• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

外泌体在缺血性心脏病中的应用的益处与挑战

Beneficial and challenges of exosome application in ischemic heart disease.

作者信息

Mardi Narges, Khanicheragh Parisa, Abbasi-Malati Zahra, Saghebasl Solmaz, Khosrowshahi Nafiseh Didar, Chegeni Sara Aghakhani, Javid Farzin, Azari Mahdiyeh, Salimi Leila, Rezabakhsh Aysa, Milani Soheil Zamen, Rahbarghazi Reza

机构信息

Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

出版信息

Stem Cell Res Ther. 2025 May 19;16(1):247. doi: 10.1186/s13287-025-04363-w.

DOI:10.1186/s13287-025-04363-w
PMID:40390086
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12090443/
Abstract

Cardiovascular diseases are the main cause of death and disability in the clinical setting. Among several pathological conditions, myocardial infarction (MI) is a common clinical finding and happens due to the reduction or complete interruption of blood support. Stem cells and progenitors are valid cell sources with significant potential to alleviate several tissue injuries. Differentiation to mature and functional cells and the release of various growth factors, and cytokines are the main reparative mechanisms by which stem cells mediate their reparative tasks. Exosomes (Exos), a subset of extracellular vesicles (EVs), exhibit great theranostic potential in biomedicine. Along with whole-cell-based therapies, the pre-clinical and clinical application of Exos has been extended in animals and humans with ischemic heart diseases (IHD). Here, in this review article, we aimed to highlight the importance of Exos in IHD and address the mechanism of action by focusing on their regenerative potential.

摘要

心血管疾病是临床环境中导致死亡和残疾的主要原因。在几种病理状况中，心肌梗死（MI）是一种常见的临床病症，它是由于血液供应减少或完全中断而发生的。干细胞和祖细胞是有效的细胞来源，具有显著减轻多种组织损伤的潜力。分化为成熟且有功能的细胞以及释放各种生长因子和细胞因子是干细胞介导其修复任务的主要修复机制。外泌体（Exos）是细胞外囊泡（EVs）的一个亚群，在生物医学中展现出巨大的诊疗潜力。随着基于全细胞的疗法，外泌体的临床前和临床应用已在患有缺血性心脏病（IHD）的动物和人类中得到扩展。在此，在这篇综述文章中，我们旨在强调外泌体在缺血性心脏病中的重要性，并通过关注其再生潜力来阐述其作用机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de1c/12090443/41fe05652b01/13287_2025_4363_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de1c/12090443/6b333718dc26/13287_2025_4363_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de1c/12090443/5dba91736abe/13287_2025_4363_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de1c/12090443/2bf38e5dfd19/13287_2025_4363_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de1c/12090443/86d557968d96/13287_2025_4363_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de1c/12090443/1ff2647115fa/13287_2025_4363_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de1c/12090443/023a8ef643cb/13287_2025_4363_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de1c/12090443/41fe05652b01/13287_2025_4363_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de1c/12090443/6b333718dc26/13287_2025_4363_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de1c/12090443/5dba91736abe/13287_2025_4363_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de1c/12090443/2bf38e5dfd19/13287_2025_4363_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de1c/12090443/86d557968d96/13287_2025_4363_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de1c/12090443/1ff2647115fa/13287_2025_4363_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de1c/12090443/023a8ef643cb/13287_2025_4363_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de1c/12090443/41fe05652b01/13287_2025_4363_Fig7_HTML.jpg

相似文献

1
Beneficial and challenges of exosome application in ischemic heart disease.外泌体在缺血性心脏病中的应用的益处与挑战
Stem Cell Res Ther. 2025 May 19;16(1):247. doi: 10.1186/s13287-025-04363-w.
2
Exosomes: promising sacks for treating ischemic heart disease?外泌体：治疗缺血性心脏病的潜力囊泡？
Am J Physiol Heart Circ Physiol. 2017 Sep 1;313(3):H508-H523. doi: 10.1152/ajpheart.00213.2017. Epub 2017 Jun 23.
3
Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position Paper from the Working Group on Cellular Biology of the Heart of the European Society of Cardiology.细胞外囊泡在缺血性心脏病的诊断和治疗中的作用：欧洲心脏病学会心脏细胞生物学工作组立场文件。
Cardiovasc Res. 2018 Jan 1;114(1):19-34. doi: 10.1093/cvr/cvx211.
4
Novel Applications of Mesenchymal Stem Cell-derived Exosomes for Myocardial Infarction Therapeutics.间充质干细胞衍生的外泌体在心肌梗死治疗中的新应用。
Biomolecules. 2020 May 2;10(5):707. doi: 10.3390/biom10050707.
5
Mesenchymal stem cell-derived exosome microRNA as therapy for cardiac ischemic injury.间充质干细胞衍生的外泌体微小RNA作为心脏缺血性损伤的治疗方法。
Biomed Pharmacother. 2021 Nov;143:112118. doi: 10.1016/j.biopha.2021.112118. Epub 2021 Sep 1.
6
miR-19a-3p containing exosomes improve function of ischaemic myocardium upon shock wave therapy.含 miR-19a-3p 的外泌体通过冲击波治疗改善缺血性心肌功能。
Cardiovasc Res. 2020 May 1;116(6):1226-1236. doi: 10.1093/cvr/cvz209.
7
Therapeutic properties of stem cell-derived exosomes in ischemic heart disease.干细胞衍生的外泌体在缺血性心脏病中的治疗特性。
Eur J Pharmacol. 2022 Apr 5;920:174839. doi: 10.1016/j.ejphar.2022.174839. Epub 2022 Feb 18.
8
Extracellular vesicle-loaded hydrogels for tissue repair and regeneration.用于组织修复和再生的细胞外囊泡负载水凝胶
Mater Today Bio. 2022 Dec 21;18:100522. doi: 10.1016/j.mtbio.2022.100522. eCollection 2023 Feb.
9
Exosomes in ischemic heart disease: novel carriers for bioinformation.缺血性心脏病中的细胞外囊泡：新型生物信息载体。
Biomed Pharmacother. 2019 Dec;120:109451. doi: 10.1016/j.biopha.2019.109451. Epub 2019 Oct 3.
10
Modified Exosomes: a Good Transporter for miRNAs within Stem Cells to Treat Ischemic Heart Disease.改性外泌体：干细胞内 miRNA 的良好载体，可用于治疗缺血性心脏病。
J Cardiovasc Transl Res. 2022 Jun;15(3):514-523. doi: 10.1007/s12265-022-10216-1. Epub 2022 Feb 28.

引用本文的文献

1
Neuroangiogenesis potential of mesenchymal stem cell extracellular vesicles in ischemic stroke conditions.间充质干细胞细胞外囊泡在缺血性中风情况下的神经血管生成潜力
Cell Commun Signal. 2025 Jun 7;23(1):272. doi: 10.1186/s12964-025-02286-w.

本文引用的文献

1
Engineering exosomes and exosome-like nanovesicles for improving tissue targeting and retention.工程化外泌体和类外泌体纳米囊泡以改善组织靶向性和滞留性。
Fundam Res. 2024 Apr 12;5(2):851-867. doi: 10.1016/j.fmre.2024.03.025. eCollection 2025 Mar.
2
Current challenges surrounding exosome treatments.外泌体治疗目前面临的挑战。
Extracell Vesicle. 2023 Dec;2:100023. doi: 10.1016/j.vesic.2023.100023. Epub 2023 Apr 29.
3
The Potential of Mesenchymal Stem Cell-Derived Exosomes in Cardiac Repair.间充质干细胞衍生外泌体在心脏修复中的潜力
Int J Mol Sci. 2024 Dec 17;25(24):13494. doi: 10.3390/ijms252413494.
4
Exosome-mediated delivery of CRISPR-Cas9: A revolutionary approach to cancer gene editing.外泌体介导的CRISPR-Cas9递送：癌症基因编辑的革命性方法。
Pathol Res Pract. 2025 Feb;266:155785. doi: 10.1016/j.prp.2024.155785. Epub 2024 Dec 19.
5
Exosomes and breast cancer angiogenesis; Highlights in intercellular communication.外泌体与乳腺癌血管生成；细胞间通讯要点
Cancer Cell Int. 2024 Dec 18;24(1):402. doi: 10.1186/s12935-024-03606-9.
6
Different storage and freezing protocols for extracellular vesicles: a systematic review.不同的细胞外囊泡储存和冷冻方案：系统综述。
Stem Cell Res Ther. 2024 Nov 26;15(1):453. doi: 10.1186/s13287-024-04005-7.
7
Inhibition of miR-194-5p avoids DUSP9 downregulation thus limiting sepsis-induced cardiomyopathy.抑制 miR-194-5p 避免了 DUSP9 的下调，从而限制了脓毒症诱导的心肌病。
Sci Rep. 2024 Sep 2;14(1):20313. doi: 10.1038/s41598-024-71166-z.
8
Xenogeneic Transplantation Promoted Human Exosome Sequestration in Rat Specific Organs.异种移植促进人外泌体在大鼠特定器官中的潴留。
Adv Pharm Bull. 2024 Jul;14(2):426-433. doi: 10.34172/apb.2024.022. Epub 2023 Dec 4.
9
Engineering Exosomes for Therapeutic Applications: Decoding Biogenesis, Content Modification, and Cargo Loading Strategies.工程外泌体用于治疗应用：解码生物发生、内容修饰和货物加载策略。
Int J Nanomedicine. 2024 Jul 16;19:7137-7164. doi: 10.2147/IJN.S464249. eCollection 2024.
10
Exosomal miRNA-21-5p and miRNA-21-3p as key biomarkers of myocardial infarction.外泌体miRNA-21-5p和miRNA-21-3p作为心肌梗死的关键生物标志物。
Health Sci Rep. 2024 Jul 9;7(7):e2228. doi: 10.1002/hsr2.2228. eCollection 2024 Jul.